AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Subscribe To Our Newsletter & Stay Updated